<DOC>
	<DOC>NCT00255047</DOC>
	<brief_summary>The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3 doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.</brief_summary>
	<brief_title>Safety and Immune Response of Different Pediatric Combination Vaccines.</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Aged ≥ 42 days and ≤ 89 days on the day of inclusion Born at full term of pregnancy (≥ 36 weeks) Informed consent form signed by the parent(s) or other legally authorized representative(s) before the 1st study related procedure Vaccination with a hepatitis B vaccine at least 30 days before inclusion Able to attend all scheduled visits and to comply with all trial procedures(i.e., access to a phone) Provide blood sample prior to Dose 1 Parent or legal representative willing to take rectal temperatures after each vaccination. Participation in another clinical trial in the 4 weeks preceding the (first)trial vaccination Planned participation in another clinical trial during the present trial period Personal or immediate family history of congenital or acquired immunodeficiency, immunosuppressive therapy such as longterm systemic corticosteroids therapy Known or suspected systemic hypersensitivity to any of the vaccine components or history of a lifethreatening reaction to a vaccine containing the same substances as the trial vaccine(s) Chronic illness that could interfere with trial conduct or completion Received blood or bloodderived products since birth Any vaccination in the 2 weeks preceding the first trial vaccination or planned in the 4 weeks after any trial vaccination. Flu vaccine could be administered only 2 weeks after any trial vaccination Previous vaccination with any acellular pertussis (DTaP) or whole cell pertussis (DTwP) based combination vaccines, Haemophilus influenzae type b (Hib)conjugate, poliovirus, or pneumococcal conjugate vaccines Coagulation disorder contraindicating intramuscular (IM) vaccination Clinically significant findings on review of systems (determined by investigator or subinvestigator to be sufficient for exclusion) Developmental delay or neurological disorder Any condition which, in the opinion of the investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Whooping cough</keyword>
	<keyword>Filamentous Haemagglutinin</keyword>
	<keyword>Fimbriae Types 2 and 3;</keyword>
	<keyword>Pertactin</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Poliovirus Types 1, 2, and 3.</keyword>
</DOC>